EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies



Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies



Journal of Pharmaceutical Sciences 97(3): 1165-1178



This study tests the hypothesis that human nasal RPMI 2650 cells grown at an air-liquid interface is a feasible model for drug transport studies via the nasal route. RPMI 2650 cells were cultured in Eagle's minimal essential medium (MEM) at both air-liquid and liquid-liquid interfaces. For each culture regimen, monolayer integrity was tested by measuring the transepithelial resistance (TEER) as well as the transport of paracellular and transcellular markers across the monolayer. The expression of tight junction proteins- differentiation markers-in cells of the different monolayers was studied by western blot analysis and confocal microscopy. The highest TEER values (192 +/- 3 Omega center dot cm(2)) were observed for RPMI 2650 cells seeded onto collagen-coated permeable polytetrafluoroethylene inserts and grown at an air-liquid interface for 10 days; a seeding density of 4 x 10(5)/cm(2) generated and maintained a cell monolayer with suitable barrier properties at days 9-12. Microscopic examination showed that RPMI 2650 cells grown on filter inserts formed a fully confluent monolayer. The apparent permeability coefficients of the paracellular marker, [C-14] mannitol, and the transcellular marker, [H-3] propranolol, were 5.07 +/- 0.01 x 10(-6) cm/s and 16.1 +/- 0.1 X 10(-6) cm/s, respectively. Western blot analysis indicated the presence of four tight junction proteins: ZO-1, occludin, claudin-1 and E-cadherin; and the quantities of ZO-1, occludin, and E-cadherin were significantly higher in cells grown at an air-liquid interface than in cells grown at a liquid-liquid interface. Confocal microscopic studies showed ZO-1, F-actin, occludin and claudin-1 proteins at cell-cell contacts and revealed significant differences in the distributions and densities of ZO-1 protein in cells grown at the two types of interface. The data indicate that RPMI 2650 cells grown at an air-liquid interface form polarized monolayers with the cells interconnected by tight junction proteins. This human nasal cell line model could provide a useful tool for in vitro screening of nasal drug candidates. (C) 2007 Wiley-Liss, Inc.

(PDF same-day service: $19.90)

Accession: 020997620

Download citation: RISBibTeXText

PMID: 17628494

DOI: 10.1002/jps.21031



Related references

Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. European Journal of Drug Metabolism and Pharmacokinetics, 2017

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology 64(11): 1621-1630, 2013

RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. European Journal of Pharmaceutics and Biopharmaceutics 74(2): 290-297, 2010

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics 107: 223-233, 2016

The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model. Pharmaceutical Research 32(2): 665-679, 2015

Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 33(4): 194-198, 1995

Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. Cytotechnology 65(3): 395-406, 2012

Cytotoxicity of Different Excipients on RPMI 2650 Human Nasal Epithelial Cells. Molecules 21(5): -, 2016

Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics 508(1-2): 22-33, 2016

Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European Journal of Pharmaceutical Sciences, 2018

Expression and functional activity of P-glycoprotein in passaged primary human nasal epithelial cell monolayers cultured by the air-liquid interface method for nasal drug transport study. Journal of Pharmacy and Pharmacology 63(3): 385-391, 2011

Roles of epidermal growth factor receptor signaling pathway on cultured human nasal epithelial cells RPMI-2650. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 44(3): 203-208, 2011

Cultivation of RPMI 265 cells as an in-vitro model for human transmucosal nasal drug absorption studies optimization of selected culture conditions. 2012

Air-liquid interface culture of serially passaged human nasal epithelial cell monolayer for in vitro drug transport studies. Drug Delivery 12(5): 305-311, 2005

The novel use of the human nasal epithelial cell line RPMI 2650 as an in vitro model to study the influence of allergens and cytokines on transforming growth factor-beta gene expression and protein release. Clinical and Experimental Allergy 35(6): 811-819, 2005